Thrivent Financial for Lutherans Makes New $43.99 Million Investment in Twist Bioscience Co. (NASDAQ:TWST)

Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience Co. (NASDAQ:TWST) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 973,713 shares of the company’s stock, valued at approximately $43,992,000. Thrivent Financial for Lutherans owned 1.66% of Twist Bioscience at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in TWST. Silvercrest Asset Management Group LLC boosted its holdings in shares of Twist Bioscience by 38.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after buying an additional 37,376 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after acquiring an additional 83,287 shares in the last quarter. Magnetar Financial LLC acquired a new stake in Twist Bioscience in the first quarter worth $389,000. Price T Rowe Associates Inc. MD increased its stake in Twist Bioscience by 7.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock valued at $1,103,000 after purchasing an additional 2,292 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in shares of Twist Bioscience during the second quarter valued at about $402,000.

Insider Activity

In other Twist Bioscience news, insider Dennis Cho sold 1,507 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the transaction, the insider now owns 91,163 shares in the company, valued at $4,375,824. This represents a 1.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 over the last three months. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $41.43 on Tuesday. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of -10.85 and a beta of 1.78. Twist Bioscience Co. has a 52-week low of $23.00 and a 52-week high of $60.90. The company has a 50-day simple moving average of $43.98 and a two-hundred day simple moving average of $46.18.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barclays decreased their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird raised their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.